DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer: An outcome-predicting and treatment-implicating study

Oncotarget

Volumn 6, Issue 2, 2015, Pages 915-934

  Lin, Hon Yi ^a,b,d   Hung, Shih Kai ^a,b   Lee, Moon Sing ^a,b   Chiou, Wen Yen ^a,b   Huang, Tze Ta ^a,b,c   Tseng, Chih En ^a,b   Shih, Liang Yu ^a,b   Lin, Ru Inn ^a,b,d   Lin, Jora M J ^d   Lai, Yi Hui ^d   Chang, Chia Bin ^d   Hsu, Feng Chun ^a   Chen, Liang Cheng ^a   Tsai, Shiang Jiun ^a   Su, Yu Chieh ^a,b   Li, Szu Chi ^a,b   Lai, Hung Chih ^a,b   Hsu, Wen Lin ^a,b   Liu, Dai Wei ^a,b   Tai, Chien Kuo ^d   Wu, Shu Fen ^d   Chan, Michael W Y ^d   more..

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Epigenetics; FHIT; Oral cancer; Radiotherapy; Resistance

Indexed keywords

AZACITIDINE; CHECKPOINT KINASE 2; CISPLATIN; DNA; FRAGILE HISTIDINE TRIAD PROTEIN; GSK 343; METHYLTRANSFERASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ACID ANHYDRIDE HYDROLASE; EZH2 PROTEIN, HUMAN; HISTONE; POLYCOMB REPRESSIVE COMPLEX 2; TUMOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER RADIOTHERAPY; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA METHYLATION; ENZYME PHOSPHORYLATION; EPIGENETICS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; MALE; MICROARRAY ANALYSIS; MOUSE; MOUTH CANCER; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; GENETIC EPIGENESIS; GENETICS; HEK293 CELL LINE; KAPLAN MEIER METHOD; METABOLISM; METHYLATION; MIDDLE AGED; MOUTH NEOPLASMS; NUDE MOUSE; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE; TUMOR VOLUME;

ACID ANHYDRIDE HYDROLASES; ANIMALS; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; HEK293 CELLS; HISTONES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHYLATION; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM PROTEINS; OUTCOME ASSESSMENT (HEALTH CARE); POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RADIATION TOLERANCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921732502     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2821     Document Type: Article

References (76)

1. NCCN.org. (2014). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancer. NCCN Guidelines™).
2. Diez-Perez R, Campo-Trapero J, Cano-Sanchez J, Lopez-Duran M, Gonzalez-Moles MA, Bascones-Ilundain J and Bascones-Martinez A. Methylation in oral cancer and pre-cancerous lesions (Review). Oncol Rep. 2011.
3. Kordi-Tamandani DM, Moazeni-Roodi AK, Rigi-Ladiz MA, Hashemi M, Birjandian E and Torkamanzehi A. Promoter hypermethylation and expression profile of MGMT and CDH1 genes in oral cavity cancer. Arch Oral Biol. 2010; 55(10):809-814.
4. Taioli E, Ragin C, Wang XH, Chen J, Langevin SM, Brown AR, Gollin SM, Garte S and Sobol RW. Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation. BMC Cancer. 2009; 9:354.
5. Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358(11):1148-1159.
6. Herman JG and Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21):2042-2054.
7. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB and Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002; 416(6880):552-556.
8. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298(5595):1039-1043.
9. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A and Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell. 2002; 111(2):185-196.
10. Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE and Simon JA. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell. 2002; 111(2):197-208.
11. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y and Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006; 439(7078):871-874.
12. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM and To KF. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002; 8(2):464-470.
13. Chan MW, Wei SH, Wen P, Wang Z, Matei DE, Liu JC, Liyanarachchi S, Brown R, Nephew KP, Yan PS and Huang TH. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res. 2005; 11(20):7376-7383.
14. Chen PC, Tsai MH, Yip S, Jou YC, Ng CF, Chen Y, Wang X, Huang W, Tung CL, Chen GC, Huang MM, Tong JH, Song EJ, Chang DC, Hsu CD, To KF, et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics. 2011; 4:45.
15. Esteller M, Corn PG, Baylin SB and Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-3229.
16. Lin HY, Huang TT, Lee MS, Hung SK, Lin RI, Tseng CE, Chang SM, Chiou WY, Hsu FC, Hsu WL, Liu DW, Su YC, Li SC and Chan MW. Unexpected close surgical margin in resected buccal cancer: Very close margin and DAPK promoter hypermethylation predict poor clinical outcomes. Oral Oncol. 2013; 49(4):336-344.
17. Huang da W, Sherman BT and Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37(1):1-13.
18. Antwih DA, Gabbara KM, Lancaster WD, Ruden DM and Zielske SP. Radiation-induced epigenetic DNA methylation modification of radiation-response pathways. Epigenetics. 2013; 8(8):839-848.
19. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM and Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996; 84(4):587-597.
20. Sparmann A and van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6(11):846-856.
21. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, Bergman Y, Simon I and Cedar H. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007; 39(2):232-236.
22. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet. 2007; 39(2):237-242.
23. Statham AL, Robinson MD, Song JZ, Coolen MW, Stirzaker C and Clark SJ. Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Res. 2012; 22(6):1120-1127.
24. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH and Issa JP. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008; 40(6):741-750.
25. Brinkman AB, Gu H, Bartels SJ, Zhang Y, Matarese F, Simmer F, Marks H, Bock C, Gnirke A, Meissner A and Stunnenberg HG. Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk. Genome Res. 2012; 22(6):1128-1138.
26. Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, Romeril SP, Burgess JL, Grant SW, Brackley JA, Graves AP, Scherzer DA, Shu A, Thompson C, Ott HM, Aller GS, et al. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012; 3(12):1091-1096.
27. Popovtzer A, Gluck I, Chepeha DB, Teknos TN, Moyer JS, Prince ME, Bradford CR and Eisbruch A. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys. 2009; 74(5):1342-1347.
28. Lee JC, Lee WH, Min YJ, Cha HJ, Han MW, Chang HW, Kim SA, Choi SH, Kim SW and Kim SY. Development of TRAIL resistance by radiation-induced hypermethylation of DR4 CpG island in recurrent laryngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2014; 88(5):1203-1211.
29. Kim EH, Park AK, Dong SM, Ahn JH and Park WY. Global analysis of CpG methylation reveals epigenetic control of the radiosensitivity in lung cancer cell lines. Oncogene. 2010.
30. Brieger J, Mann SA, Pongsapich W, Koutsimpelas D, Fruth K and Mann WJ. Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells. Int J Mol Med. 2012; 29(3):505-509.
31. De Schutter H, Kimpe M, Isebaert S and Nuyts S. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2009; 73(3):904-912.
32. Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, Yendamuri S, Vecchione A, Trapasso F and Croce CM. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res. 2003; 63(6):1183-1187.
33. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM and Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA. 1997; 94(25):13771-13776.
34. Saldivar JC, Miuma S, Bene J, Hosseini SA, Shibata H, Sun J, Wheeler LJ, Mathews CK and Huebner K. Initiation of Genome Instability and Preneoplastic Processes through Loss of Fhit Expression. PLoS Genet. 2012; 8(11):e1003077.
35. Lin YX, Yu F, Gao N, Sheng JP, Qiu JZ and Hu BC. microRNA-143 protects cells from DNA damage-induced killing by downregulating FHIT expression. Cancer Biother Radiopharm. 2011; 26(3):365-372.
36. Kapitanovic S, Cacev T, Loncar B, Catela Ivkovic T, Krizanac S and Pavelic K. Reduced FHIT expression is associated with tumor progression in sporadic colon adenocarcinoma. Exp Mol Pathol. 2014; 96(1):92-97.
37. Momcilovic O, Choi S, Varum S, Bakkenist C, Schatten G and Navara C. Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and G(2) but not G(1) cell cycle arrest in pluripotent human embryonic stem cells. Stem Cells. 2009; 27(8):1822-1835.
38. Zhou W, Sun M, Li GH, Wu YZ, Wang Y, Jin F, Zhang YY, Yang L and Wang DL. Activation of the phosphorylation of ATM contributes to radioresistance of glioma stem cells. Oncol Rep. 2013; 30(4):1793-1801.
39. Wang WJ, Wu SP, Liu JB, Shi YS, Huang X, Zhang QB and Yao KT. MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. Cancer Res. 2013; 73(3):1219-1231.
40. Rainey MD, Black EJ, Zachos G and Gillespie DA. Chk2 is required for optimal mitotic delay in response to irradiation-induced DNA damage incurred in G2 phase. Oncogene. 2008; 27(7):896-906.
41. Gogineni VR, Nalla AK, Gupta R, Dinh DH, Klopfenstein JD and Rao JS. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett. 2011; 313(1):64-75.
42. Chen C, Shimizu S, Tsujimoto Y and Motoyama N. Chk2 regulates transcription-independent p53-mediated apoptosis in response to DNA damage. Biochem Biophys Res Commun. 2005; 333(2):427-431.
43. Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH and Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell. 2010; 18(6):619-629.
44. Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, Nagashima K, Sawa H, Ikeda K and Motoyama N. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 2002; 21(19):5195-5205.
45. Yutori H, Semba S, Komori T and Yokozaki H. Restoration of fragile histidine triad expression restores Chk2 activity in response to ionizing radiation in oral squamous cell carcinoma cells. Cancer Sci. 2008; 99(3):524-530.
46. Han SY, Iliopoulos D, Druck T, Guler G, Grubbs CJ, Pereira M, Zhang Z, You M, Lubet RA, Fong LY and Huebner K. CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors. Oncogene. 2004; 23(22):3990-3998.
47. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M and Ishizaki K. Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res. 1998; 58(15):3429-3434.
48. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF and Minna JD. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 2001; 61(9):3581-3585.
49. Chang KW, Kao SY, Tzeng RJ, Liu CJ, Cheng AJ, Yang SC, Wong YK and Lin SC. Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J Pathol. 2002; 196(3):300-306.
50. Mielcarek-Kuchta D, Paluszczak J, Seget M, Kiwerska K, Biczysko W, Szyfter K and Szyfter W. Prognostic factors in oral and oropharyngeal cancer based on ultrastructural analysis and DNA methylation of the tumor and surgical margin. Tumour Biol. 2014; 35(8):7441-7449.
51. Joo YH, Park SW, Jung SH, Lee YS, Nam IC, Cho KJ, Park JO, Chung YJ and Kim MS. Recurrent loss of the FHIT gene and its impact on lymphatic metastasis in early oral squamous cell carcinoma. Acta Otolaryngol. 2013; 133(9):992-999.
52. Ribeiro IP, Marques F, Caramelo F, Ferrao J, Prazeres H, Juliao MJ, Rifi W, Savola S, de Melo JB, Baptista IP and Carreira IM. Genetic imbalances detected by multiplex ligation-dependent probe amplification in a cohort of patients with oral squamous cell carcinoma-the first step towards clinical personalized medicine. Tumour Biol. 2014; 35(5):4687-4695.
53. Tanimoto K, Hayashi S, Tsuchiya E, Tokuchi Y, Kobayashi Y, Yoshiga K, Okui T, Kobayashi M and Ichikawa T. Abnormalities of the FHIT gene in human oral carcinogenesis. Br J Cancer. 2000; 82(4):838-843.
54. O'Hagan HM, Mohammad HP and Baylin SB. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet. 2008; 4(8):e1000155.
55. Ayrapetov MK, Gursoy-Yuzugullu O, Xu C, Xu Y and Price BD. DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin. Proc Natl Acad Sci USA. 2014; 111(25):9169-9174.
56. Ahuja N, Easwaran H and Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest. 2014; 124(1):56-63.
57. Kim JG, Park MT, Heo K, Yang KM and Yi JM. Epigenetics meets radiation biology as a new approach in cancer treatment. Int J Mol Sci. 2013; 14(7):15059-15073.
58. Groselj B, Sharma NL, Hamdy FC, Kerr M and Kiltie AE. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer. 2013; 108(4):748-754.
59. Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM and Tombolini V. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010; 9:305.
60. Palanichamy K and Chakravarti A. Combining drugs and radiotherapy: from the bench to the bedside. Curr Opin Neurol. 2009; 22(6):625-632.
61. Li Y, Geng P, Jiang W, Wang Y, Yao J, Lin X, Liu J, Huang L, Su B and Chen H. Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells. Tumour Biol. 2014; 35(5):4831-4839.
62. Wang L, Zhang Y, Li R, Chen Y, Pan X, Li G, Dai F and Yang J. 5-aza-2'-Deoxycytidine enhances the radiosensitivity of breast cancer cells. Cancer Biother Radiopharm. 2013; 28(1):34-44.
63. Hofstetter B, Niemierko A, Forrer C, Benhattar J, Albertini V, Pruschy M, Bosman FT, Catapano CV and Ciernik IF. Impact of genomic methylation on radiation sensitivity of colorectal carcinoma. Int J Radiat Oncol Biol Phys. 2010; 76(5):1512-1519.
64. Patties I, Jahns J, Hildebrandt G, Kortmann RD and Glasow A. Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines. Strahlenther Onkol. 2009; 185(5):331-338.
65. Maeder ML, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, Ho QH, Sander JD, Reyon D, Bernstein BE, Costello JF, Wilkinson MF and Joung JK. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol. 2013; 31(12):1137-1142.
66. Jan JC, Hsu WH, Liu SA, Wong YK, Poon CK, Jiang RS, Jan JS and Chen IF. Prognostic factors in patients with buccal squamous cell carcinoma: 10-year experience. J Oral Maxillofac Surg. 2011; 69(2):396-404.
67. Chiou WY, Lin HY, Hsu FC, Lee MS, Ho HC, Su YC, Lee CC, Hsieh CH, Wang YC and Hung SK. Buccal mucosa carcinoma: surgical margin less than 3 mm, not 5 mm, predicts locoregional recurrence. Radiat Oncol. 2010; 5:79.
68. Sutton DN, Brown JS, Rogers SN, Vaughan ED and Woolgar JA. The prognostic implications of the surgical margin in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2003; 32(1):30-34.
69. Upile T, Fisher C, Jerjes W, El Maaytah M, Searle A, Archer D, Michaels L, Rhys-Evans P, Hopper C, Howard D and Wright A. The uncertainty of the surgical margin in the treatment of head and neck cancer. Oral Oncol. 2007; 43(4):321-326.
70. Chen TC, Wang CP, Ko JY, Yang TL and Lou PJ. The impact of pathologic close margin on the survival of patients with early stage oral squamous cell carcinoma. Oral Oncol. 2012; 48(7):623-628.
71. Meier JD, Oliver DA and Varvares MA. Surgical margin determination in head and neck oncology: current clinical practice. The results of an International American Head and Neck Society Member Survey. Head Neck. 2005; 27(11):952-958.
72. Nason RW, Binahmed A, Pathak KA, Abdoh AA and Sandor GK. What is the adequate margin of surgical resection in oral cancer? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107(5):625-629.
73. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK and Lefebvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27(10):843-850.
74. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, Genden E, Urken ML and Wang BY. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005; 29(2):167-178.
75. Tsai WT, Lee MS, Hung SK, Chiou WY, Huang TT, Tseng CE, Chang SM, Hsu FC, Su YC and Li SC. A very close margin of =1 mm predicts a poor outcome in resected buccal cancer patients with a pathological margin of =3 mm. Tzu Chi Medical Journal. 2011.
76. Greene FL. (2006). AJCC cancer staging atlas. (New York, NY: Springer).